Investigator’s Brochure: BNT162/PF-07302048

BioNTech RNA Pharmaceuticals GmbH The development of a ribonucleic acid (RNA)-based vaccine encoding a viral antigen that is translated by the vaccinated organism to protein to induce a protective immune response provides significant advantages over more conventional vaccine approaches. At BioNTech, there are three different RNA platforms under development, namely non- modified uridine containing mRNA […]